Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Trial of Ipilimumab + Nivolumab in Resected Melanoma
NCT02970981Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by NYU Langone Health. Primary endpoint: Relapse-Free Survival at 48 months. Started Nov 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02970981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970981.